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Abstract
Background/Aim: Intima media thickness (IMT) and stiff-
ness of the carotid arteries is related to coronary artery
disease, and chronic renal failure patients are at high risk
for such diseases. An oral adsorbent, AST-120 (Kreme-
zin; Kureha Chemical Industry, Tokyo, Japan), can delay
the progression of chronic renal failure in undialyzed
uremic patients. The aim of the present study was to
determine whether AST-120 affects carotid artery IMT
and pulse wave velocity (PWV) in patients with chronic
renal failure not undergoing dialysis. Methods: Fifty pa-
tients with non-diabetic chronic renal failure were ran-
domly divided into two groups: 30 patients (18 men and
12 women; mean age 53.5 years; mean serum creatinine
3.2 mg/dl) who were given AST-120 (6.0 g/day) and 20
patients (12 men and 8 women; mean age 52.0 years;
mean serum creatinine 3.5 mg/dl) who were not given
AST-120. Thirty healthy age-matched subjects (18 men
and 12 women; mean age 51.5 years; mean serum creati-
nine 0.9 mg/dl) were also included. The treatment period
was 24 months. IMT and arterial stiffness were measured
before and after treatment. Results:  The slope of the
reciprocal serum creatinine concentration over time be-
came significantly less steep in the AST-120 group than
in the non-AST-120 group (p ! 0.001). Before treatment,
carotid artery IMT differed little between the AST-120
group (0.90 B 0.22 mm) and the non-AST-120 group
(0.88 B 0.20 mm). IMT in these two groups was signifi-
cantly greater than IMT in the control group (0.64 B
0.14 mm) (p ! 0.01). Carotid IMT in the AST-120 group
decreased slightly but not significantly to 0.84 B
0.20 mm after 12 months and then significantly after 24
months to 0.78 B 0.18 mm (p ! 0.05). Carotid IMT in the
non-AST group showed little change throughout the
experimental period. PWV differed little between the
AST-120 group (1,980 B 330 cm/s) and the non-AST
group (1,940 B 360 cm/s) before treatment. PWV values
in these two groups were significantly greater than PWV
in the control group (1,280 B 240 cm/s) (p ! 0.01). After
12 and 24 months, PWV in the AST-120 group decreased
significantly to 1,840 B 280 cm/s (p ! 0.05) and to 1,780
B 260 cm/s (p ! 0.05), respectively; however, PWV in the
non-AST group showed a slight increase during the
experimental period. Conclusion: The data suggest that
AST-120 may reduce arterial stiffness and IMT in non-
diabetic chronic renal failure patients before dialysis.
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Introduction
An increase in carotid artery intima-media thickness
(IMT) has been associated with atherosclerotic risk fac-
tors [1]. Shoji et al. [2] reported that hemodialysis patients
have more than ten times higher relative risk for death
from cardiovascular diseases and that these patients have
advanced arterial wall changes, as shown by increased
IMT of the carotid arteries. Increased arterial stiffness is a
pathological state closely associated with atherosclerotic
cardiovascular disease. Pulse wave velocity (PWV) is an
indicator of arterial stiffness and a marker of vascular
injury [3, 4]. Arterial wall stiffness predicts all-cause and
cardiovascular mortality in chronic renal failure patients
including dialysis patients; thus, monitoring PWV is use-
ful for predicting all-cause and cardiovascular mortality
in chronic renal failure patients [5].
Circulating uremic toxins are thought to be involved in
the progression of chronic renal failure [6]. An oral adsor-
bent, AST-120, is effective in removing uremic toxins
including indoxyl sulfate and can delay the progression of
chronic renal failure and the need for dialysis in uremic
patients [7]. Little is known, however, about the effect of
AST-120 on atherosclerosis in undialyzed chronic renal
failure patients. In the present study, we assessed carotid
IMT and PWV in undialyzed chronic renal failure pa-
tients with and without AST-120 treatment.
Patients and Methods
Fifty patients with non-diabetic chronic renal failure were di-
vided into two groups at random by sealed envelope method: 30
patients (18 men and 12 women; mean age 53.5 years; mean serum
creatinine 3.2 mg/dl) given AST-120 (Kremezin; Kureha Chemical
Industry, Tokyo, Japan) (6.0 g/day for 24 months) and 20 patients
(12 men and 8 women; mean age 52.0 years; mean serum creatinine
3.5 mg/dl) not given AST-120. Thirty age-matched healthy volun-
teers (18 men and 12 women; mean age 51.5 years; mean serum cre-
atinine 0.9 mg/dl) were also included as control subjects. AST-120
consists of fine spherical particles, approximately 0.2–0.4 mm in
diameter, composed of porous microcrystalline carbon with an oxy-
gen complex including a surface oxide as described previously [8].
AST-120 is not soluble in water. It adsorbs a negligible amount of
digestive enzymes in contrast to conventional charcoal, and cannot
be decomposed by digestive enzymes and intestinal bacteria [8]. This
study was pre-approved by our human research ethics committees.
Informed consent was obtained from each participant.
The slope of the reciprocal serum creatinine concentration over
time was calculated three times to assess the changes in renal func-
tion as described previously [9, 10]. The slope of the regression line is
substituted as the progression speed of renal failure. Carotid IMT
and PWV were determined upon entrance into the study and at 12
and 24 months of after the start of AST-120. High-resolution B-mode
ultrasound examination was done with a 7.5-MHz mechanical sector
transducer on the Aloka SSD-2000 (Aloka Co., Ltd, Tokyo, Japan).
An experienced technologist who was kept unaware of the patients’
clinical data made all ultrasound measurements (scans and image
analyses) using the same equipment as described previously by oth-
ers [11, 12]. Carotid IMT was measured at points 20, 25 and 30 mm
proximal to the flow divider on the far wall of the right and left com-
mon carotid arteries at the end of the diastolic phase [13], and mean
IMT was calculated for each individual. The greatest value from the
six averaged IMTs (three from the left and three from the right) was
used as the representative value for each individual [14]. When a
plaque was observed in the region of common carotid artery mea-
surements, IMT was not determined. Brachial-ankle PWV was mea-
sured by means of a pulse pressure analyzer (model BP-203RPE;
Nihon Colin, Tokyo, Japan). This instrument records PWV, blood
pressure, electrocardiogram, and heart sounds simultaneously [4].
Patients were examined in a supine position. Electrocardiographic
electrodes were placed on both wrists, a microphone for detecting
heart sounds was placed on the left edge of the sternum, and sphyg-
momanometer cuffs were wrapped on both upper arms and ankles.
Pulse waves were recorded via sensors placed on both posterior tibial
arteries. The time intervals required for the pulse waves to travel
from the heart to both posterior tibial arteries were measured, and
the distance between the heart and each posterior tibial artery was
estimated on the basis of the patient’s height. The best 10 consecutive
pulses were analyzed, and the average PWV from the heart to the
posterior tibial artery was calculated by dividing the distance by the
time interval. Two measurements were taken in each leg, and the
average value was used for analysis. PWV was expressed in centime-
ters per second. The PWV coefficient of variation was less than 5%.
Blood total cholesterol, HDL cholesterol, LDL cholesterol, triglycer-
ide, and C-reactive protein (CRP) were measured. All blood samples
were obtained in the morning with patients in a fasting state. Urinary
protein excretion (24-hour) was measured by Lowry method before
and after treatments.
Data  are  expressed  as  mean  B SD.  Wilcoxon  matched-pairs
signed-ranks test or two-way analysis of variance was used for statis-
tical analysis. The independent variables for PWV and IMT were
evaluated by multiple regression analysis. A p value of !0.05 was
considered statistically significant.
Results
Patient characteristics and laboratory data including
age, sex, blood pressure, and lipid and CRP levels were
similar for the AST-120-treated and untreated patients at
the beginning of the study (table 1). Table 2 depicts the
results of stepwise multiple regression analysis between
IMT and PWV and other clinical variables. Total choles-
terol, HDL cholesterol, LDL cholesterol triglyceride, CRP
levels and body weight differed little during the experi-
mental period between each group. However, urinary pro-
tein excretion decreased after treatment in both groups
(p ! 0.05) (table 3). The slope of the reciprocal serum cre-
atinine concentration over time became significantly less
steep in the AST-120-treated group (–0.006 B 0.002 dl/Effect of AST-120 on Atherosclerosis Kidney Blood Press Res 2004;27:121–126 123
mg per month) than in the untreated group (–0.002 B
0.002 dl/mg per month, p ! 0.001) (fig. 1). Changes in
PWV and carotid IMT after treatment in both groups are
shown in table 4. At the start of the study, carotid IMT
was similar in both groups (AST-120-treated group, mean
0.90 B 0.22  mm  and  untreated  group,  mean  0.88  B
0.20 mm). Values in these groups were significantly high-
er than those in the control group (0.64 B 0.14 mm) (p !
0.01). Carotid IMT in the AST-120 treatment group was
decreased slightly but not significantly at 12 months (0.84
B 0.20 mm) and was then decreased significantly at 24
months (0.78 B 0.18 mm) (p ! 0.05). Carotid IMT in the
untreated group showed little change throughout the ex-
perimental period. PWV differed little between the AST-
120-treated group (1,980 B 330 cm/s) and the untreated
group (1,940 B 360 cm/s) at the start of the study, and the
values in these two groups were significantly higher than
those in the control group (1,280 B 240 cm/s) (p ! 0.01).
PWV in the AST-120-treated group was decreased signifi-
cantly at 12 months to 1,840 B 280 cm/s (p ! 0.05) and at
24 months to 1,780 B 260 cm/s (p ! 0.05). However,
PWV in the untreated group was increased slightly but
not significantly to 2,020 B 380 cm/s at 12 months and to
2,140 B 410 cm/s (p ! 0.05) at 24 months.
Discussion
In the present study, 24-month treatment with oral
adsorbent  AST-120  significantly  reduced  carotid  IMT
and PWV in undialyzed chronic renal failure patients.
Blacher et al. [15] reported that the presence of atheroscle-
rosis can lead to stiffening of the arteries, which in turn
can lead to atherosclerosis. PWV is a strong independent
predictor of overall and cardiovascular mortality in pa-
tients  with  end-stage  renal  disease  [16].  Hemodialysis
patients have advanced arterial wall changes as shown by
increased carotid IMT which is an index to other arteries;
they also have arterial stiffness, as shown by increased
PWV [2]. Shoji et al. [2] reported advanced atherosclero-
sis in patients before the start of hemodialysis, and that
the  condition  is  due  to  chronic  renal  failure  and/or
Table 1. Baseline clinical characteristics in the two patient groups
AST-120
(n = 30)
No AST-120
(n = 20)
Sex, male/female 18/12 12/8
Age, years 53.5B10.5 52.0B9.5
Systolic BP, mm Hg 132.6B14.6 136.8B14.0
Diastolic BP, mm Hg 82.6B10.0 83.0B9.8
Serum creatinine, mg/dl 3.2B1.0 3.5B1.1
Blood urea nitrogen, mg/dl 34.2B6.5 36.5B7.5
C-reactive protein, mg/dl 1.12B0.22 1.22B0.24
Total cholesterol, mg/dl 236B28 226B26
Triglyceride, mg/dl 172B20 165B16
LDL cholesterol, mg/dl 174B32 166B24
HDL cholesterol, mg/dl 38B836 B7
Antihypertensive drug
Yes  ACEI 8 5
ARB 10 5
Ca antagonists 8 4
Others 4 3
No 15 10
Statin
Yes 10 6
No 20 14
Smokers 10 (33%) 6 (30%)
BP = Blood pressure; CRP = C-reactive protein; ACEI = angio-
tensin-converting enzyme inhibitor; ARB = angiotensin II receptor
blocker.
Table 2. Results of stepwise multiple
regression analysis to assess the correlation
of IMT and PWV with other variables
Covariate IMT
ß t p value
PWV
ß t p value
Age 0.30 30.6 0.01 0.34 43.5 0.01
Sex 0.2310.8 0.01 0.08 9.86 0.01
SBP 0.34 17.5  0.01 0.46 58.6 0.01
Smoking –0.008 –1.26 NS –0.001 –0.23NS
Total cholesterol –0.014 –1.68 NS –0.012 –1.58 NS
Triglyceride –0.04 –5.30 0.01  0.05 5.7 0.01
SBP = Systolic blood pressure.124 Kidney Blood Press Res 2004;27:121–126 Nakamura/Kawagoe/Matsuda/Ueda/
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Fig. 1. Slopes of the reciprocal serum creatinine concentration over
time in the AST-120-treated (right) and untreated groups (left). The
mean of the each patient’s slope in the 6-month observation period
before the treatment is indicated by a dotted line and its line is
lengthened in the 24-month treatment period in assumption with the
progression speed of natural course. Because dialysis is usually ini-
tiated when serum creatinine levels reach 10.0 mg/dl [19], we esti-
mated the time of the initiation of dialysis by calculating the point
that a dotted slope crosses over a line of the reciprocal of serum creat-
inine (1/creatinine = 0.1) as the surrogate of the actual time of the
initiation of dialysis.
Table 3. Changes in blood lipid values, CRP, proteinuria and body weight before and 24 months after AST-120
treatment
AST-120 (n = 30)
before after
no AST-120 (n = 20)
before after
Total cholesterol, mg/dl 236B28 224B26 226B26 230B29
Triglyceride, mg/dl 170B20 168B22 165B16 170B18
LDL cholesterol, mg/dl 174B321 6 6 B28 166B24 172B26
HDL cholesterol, mg/dl 38B836 B10 36B734 B8
C-reactive protein, mg/dl 1.12B0.22 1.18B0.26 1.22B0.24 1.28B0.28
Proteinuria, g/day 1.6B0.6 1.1B0.4* 1.4B0.6 1.0B0.3*
Body weight, kg 58.8B8.6 56.9B8.2 59.2B9.4 58.0B8.6
Blood lipid values, CRP levels and body weight differed little during the experimental period between each group
before and after AST-120 treatment.
Proteinuria: * p ! 0.05 before versus after treatment.
Table 4. Pulse wave velocity (PWV) and
carotid artery intima-media thickness
(IMT) in the two patient groups and the
control group
AST-120 No AST-120 Healthy controls
PWV, cm/s
Before 1,980B330* 1,940B360* 1,280B240
12 months 1,840B280** 2,020B380
24 months 1,780B260** 2,140B410**
IMT, mm
Before 0.90B0.22* 0.88B0.20* 0.64B0.14
12 months 0.84B0.20 0.90B0.24
24 months 0.78B0.18** 0.93B0.26
* Versus healthy controls, p ! 0.01. ** Versus before, p ! 0.05.Effect of AST-120 on Atherosclerosis Kidney Blood Press Res 2004;27:121–126 125
secondary  metabolic  alterations  that  promote  vascular
changes. Data obtained in the Zoungas et al. study [17]
and our present study, showing IMT to be significantly
greater in undialyzed chronic renal failure patients than in
controls, matched data obtained by Shoji et al. [2]. Ichiha-
ra et al. [5] recently reported that long-term administra-
tion  of  fluvastatin  prevents  further  decline  of  arterial
biomechanics in hemodialysis patients. However, the ef-
fect  of  AST-120  on  PWV  and/or  IMT  in  undialyzed
chronic renal failure patients has not been clarified.
Uremic toxins are thought to be involved in the pro-
gressive loss of intact nephrons in chronic renal failure
patients [18]. AST-120, which removes uremic toxins, has
been reported to delay the need for dialysis in patients
with end-stage renal disease, and it may also slow the pro-
gression of advanced chronic renal failure [19]. Recently,
Sanaka et al. [20] reported that AST-120 attenuates or
arrests the progression in a fairly large number of chronic
renal failure patients. In the present study, AST-120 at
6.0 g/day preserved renal function longer in treated than
in non-treated patients. Dialysis is usually started when
serum creatinine levels reach 8.0–10.0 mg/dl or creatinine
clearance is !10.0 ml/min. Our data suggest that hemodi-
alysis was postponed longer by starting AST-120 treat-
ment in patients with early chronic renal failure rather
than  waiting  until  chronic  renal  failure  was  more  ad-
vanced, as also suggested by Yorioka et al. [19]. Although
AST-120 adsorbs only a small amount of creatinine in the
intestine, it does not significantly reduce urinary excre-
tion of creatinine [8]. The beneficial effects of AST-120 on
renal dysfunction may not be due to its direct adsorption
of creatinine in the intestine. In the present study, AST-
120 did not change blood pressure, body weight and lipid
values. Since circulating uremic toxins including indoxyl
sulfate are thought to be involved in the progression of
chronic renal failure, adsorption of these toxins may be
useful in the treatment of chronic renal failure [7, 19].
Niwa et al. [7] reported that AST-120 could reduce serum
and urine levels of indoxyl sulfate in chronic renal failure
patients. However, we did not measure indoxyl sulfate in
the present study. Some investigators have reported that
AST-120  decreases  expression  of  transforming  growth
factor-ß  and  tissue  inhibitor  of  metalloproteinase-1
(TIMP), both of which contribute to the progression of
renal fibrosis and glomerulosclerosis [21, 22]. Matrix me-
talloproteinases (MMPs) play a role in the progression of
atherosclerosis. Atherosclerotic regions show locally in-
creased  expression  of  MMPs  including  MMP-9  [23].
Blood MMP-9 levels are elevated in patients with unsta-
ble plaque and acute myocardial infarction, suggesting
that MMP-9 contributes to acute coronary syndrome [24].
We reported previously that MMP-9 mRNA expression
was enhanced in peripheral blood monocytes obtained
from hemodialysis patients and that this enhancement
may be involved in the development of cardiovascular
complications  in  these  patients  [25].  In  addition,  we
reported  that  blood  TIMP-1  and  MMP-9  levels  were
increased in chronic renal failure patients and that AST-
120  was  effective  in  reducing  these  concentrations  in
chronic renal failure patients [26]. Therefore, AST-120
may be effective in ameliorating atherosclerosis. We are
now  studying  blood  cytokine  levels  including  TGF-ß,
MMP-9 and TIMP-1 levels and atherosclerosis precursors
before and after AST-120 treatment in chronic renal fail-
ure patients. Our present data seem to strengthen this
hypothesis.  However,  the  precise  mechanisms  are  still
unclear. AST-120 has been shown to improve plasma lip-
id abnormalities in uremic rats by binding to bile acids in
the intestinal lumen and preventing their reabsorption as
well  as  by  preventing  a  decrease  in  lipoprotein  lipase
activity [27]. However, lipid values in the present study
differed little during the experimental period. The effect
of AST-120 on lipid metabolism in chronic renal failure
patients must be investigated in detail. In addition, we
showed that proteinuria decreased after treatment in both
AST-120-treated and non-treated groups. This may be, in
part, due to other drugs such as angiotensin-converting
enzyme  inhibitors  or  statins,  but  not  due  to  AST-120
itself.
In summary, the present data suggest that AST-120 is
effective  in  preventing  progressive  atherosclerosis  in
chronic renal failure patients, as assessed by estimates of
PWV and carotid artery IMT.
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